AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Adenoma, ChromophobeAdenomaAdenoma, OxyphilicKidney NeoplasmsCarcinoma, Renal CellPituitary NeoplasmsKeratin-7Adenoma, PleomorphicAdenoma, VillousAdenocarcinoma, Clear CellCalbindin 1Carcinoma, PapillaryMyelin and Lymphocyte-Associated Proteolipid ProteinsAdrenocortical AdenomaAdenoma, Liver CellBirt-Hogg-Dube SyndromeParvalbuminsImmunohistochemistryNephrectomyChromosomes, Human, Pair 10Tumor Markers, BiologicalAdaptor Protein Complex mu SubunitsChromosomes, Human, Pair 1Ossification, HeterotopicChromosomes, Human, Pair 2Growth Hormone-Secreting Pituitary AdenomaColorectal NeoplasmsColonic PolypsACTH-Secreting Pituitary AdenomaAdaptor Protein Complex 1Keratin-20In Situ Hybridization, FluorescenceChromosomes, Human, Pair 6NeprilysinTissue Array AnalysisAdenoma, AcidophilColonoscopyAdenomatous PolypsCalbindinsProlactinomaKidneyChromosomes, Human, Pair 17Adenoma, BasophilChromosome AberrationsAdrenal Cortex NeoplasmsKeratinsOligonucleotide Array Sequence AnalysisGene Expression ProfilingDNA, NeoplasmGene Expression Regulation, NeoplasticReverse Transcriptase Polymerase Chain ReactionImmunoenzyme TechniquesAdenomatous Polyposis ColiNeoplasm ProteinsAcromegalyCushing SyndromeGenes, APCRNA, MessengerPrognosisMembrane ProteinsHyperparathyroidismSalivary Gland NeoplasmsColonic NeoplasmsIntestinal NeoplasmsHyperplasiaNeoplasms, Multiple PrimaryAdrenal Gland NeoplasmsPituitary ACTH HypersecretionParotid NeoplasmsCarcinomaHyperaldosteronismSphenoid BoneDuodenal NeoplasmsAdrenocorticotropic HormonePituitary GlandAdenocarcinomaHyperparathyroidism, PrimaryThyroid NeoplasmsPrecancerous ConditionsSella TurcicaSigmoidoscopy
Adenoma, Chromophobe: A benign tumor of the anterior pituitary in which the cells do not stain with acidic or basic dyes.Adenoma: A benign epithelial tumor with a glandular organization.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Adenoma, Pleomorphic: A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)Adenoma, Villous: An adenoma of the large intestine. It is usually a solitary, sessile, often large, tumor of colonic mucosa composed of mucinous epithelium covering delicate vascular projections. Hypersecretion and malignant changes occur frequently. (Stedman, 25th ed)Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Calbindin 1: A calcium-binding protein that mediates calcium HOMEOSTASIS in KIDNEYS, BRAIN, and other tissues. It is found in well-defined populations of NEURONS and is involved in CALCIUM SIGNALING and NEURONAL PLASTICITY. It is regulated in some tissues by VITAMIN D.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Myelin and Lymphocyte-Associated Proteolipid Proteins: A family of MARVEL domain-containing proteolipid proteins involved in vesicular trafficking cycling between the GOLGI COMPLEX and the apical PLASMA MEMBRANE.Adrenocortical Adenoma: A benign neoplasm of the ADRENAL CORTEX. It is characterized by a well-defined nodular lesion, usually less than 2.5 cm. Most adrenocortical adenomas are nonfunctional. The functional ones are yellow and contain LIPIDS. Depending on the cell type or cortical zone involved, they may produce ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE.Adenoma, Liver Cell: A benign epithelial tumor of the LIVER.Birt-Hogg-Dube Syndrome: Autosomal dominant neoplastic syndrome characterised by genodermatosis, lung cysts, spontaneous and recurrent PNEUMOTHORAX; and RENAL CANCER. It is associated with mutations in the folliculin protein gene (FLCN protein).Parvalbumins: Low molecular weight, calcium binding muscle proteins. Their physiological function is possibly related to the contractile process.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Nephrectomy: Excision of kidney.Chromosomes, Human, Pair 10: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Adaptor Protein Complex mu Subunits: A family of medium adaptin protein subunits of approximately 45 KDa in size. They have been primarily found as components of ADAPTOR PROTEIN COMPLEX 3 and ADAPTOR PROTEIN COMPLEX 4.Chromosomes, Human, Pair 1: A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.Ossification, Heterotopic: The development of bony substance in normally soft structures.Chromosomes, Human, Pair 2: A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.Growth Hormone-Secreting Pituitary Adenoma: A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Colonic Polyps: Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.ACTH-Secreting Pituitary Adenoma: A pituitary adenoma which secretes ADRENOCORTICOTROPIN, leading to CUSHING DISEASE.Adaptor Protein Complex 1: A clathrin adaptor protein complex primarily involved in clathrin-related transport at the TRANS-GOLGI NETWORK.Keratin-20: A type I keratin expressed predominately in gastrointestinal epithelia, MERKEL CELLS, and the TASTE BUDS of the oral mucosa.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Chromosomes, Human, Pair 6: A specific pair GROUP C CHROMSOMES of the human chromosome classification.Neprilysin: Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Adenoma, Acidophil: A benign tumor, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumors may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhea. (Dorland, 27th ed)Colonoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the colon.Adenomatous Polyps: Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)Calbindins: Calcium-binding proteins that are found in DISTAL KIDNEY TUBULES, INTESTINES, BRAIN, and other tissues where they bind, buffer and transport cytoplasmic calcium. Calbindins possess a variable number of EF-HAND MOTIFS which contain calcium-binding sites. Some isoforms are regulated by VITAMIN D.Prolactinoma: A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Chromosomes, Human, Pair 17: A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.Adenoma, Basophil: A small tumor of the anterior lobe of the pituitary gland whose cells stain with basic dyes. It may give rise to excessive secretion of ACTH, resulting in CUSHING SYNDROME. (Dorland, 27th ed)Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.DNA, Neoplasm: DNA present in neoplastic tissue.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Adenomatous Polyposis Coli: A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Acromegaly: A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.Genes, APC: Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with familial adenomatous polyposis (ADENOMATOUS POLYPOSIS COLI) and GARDNER SYNDROME, as well as some sporadic colorectal cancers.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Colonic Neoplasms: Tumors or cancer of the COLON.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Adrenal Gland Neoplasms: Tumors or cancer of the ADRENAL GLANDS.Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Hyperaldosteronism: A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.Sphenoid Bone: An irregular unpaired bone situated at the SKULL BASE and wedged between the frontal, temporal, and occipital bones (FRONTAL BONE; TEMPORAL BONE; OCCIPITAL BONE). Sphenoid bone consists of a median body and three pairs of processes resembling a bat with spread wings. The body is hollowed out in its inferior to form two large cavities (SPHENOID SINUS).Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Adrenocorticotropic Hormone: An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).Pituitary Gland: A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Hyperparathyroidism, Primary: A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Sella Turcica: A bony prominence situated on the upper surface of the body of the sphenoid bone. It houses the PITUITARY GLAND.Sigmoidoscopy: Endoscopic examination, therapy or surgery of the sigmoid flexure.

Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. (1/47)

Profound thrombocytopenia developed in a patient during treatment with heparin for venous thrombosis. The platelet count increased toward normal when heparin administration was stopped, but fell abruptly when the drug was again given. Platelet aggregation occurred when heparin was added to the patient's platelet-rich plasma, or to normal platelets plus the patient's serum. This serum also effected release of 3H-serotonin from normal platelets. This pattern of aggregation was clearly different from that occasionally caused by heparin in a control population. The data is consistent with an effect of heparin on platelets, possibly mediated by on immune mechanism.  (+info)

Visual failure from pituitary and parasellar tumours occurring with favourable outcome in pregnant women. (2/47)

Very few cases have been reported of a successful outcome after relief by operation of severe visual failure from a pituitary or other parasellar tumour during the late stages of pregnancy. Two such cases are recorded here together with the obstetric features and follow-up studies of more than three years. Usually the deterioration of vi sion occurs in the latter half of the pregnancy and recovers rapidly after delivery, whether the onset of labour has occurred spontaneously or after induction. In subsequent pregnancies vision deteriorates at an earlier stage and becomes even more marked. Some cases are now occurring even in pregnancies induced by modern fertility drugs. The treatment of choice whenever vision is seriously threatened at any stage of pregnancy is a surgical attack on the pituitary, followed by suitable replacement therapy to ensure that the pregnancy continues.  (+info)

Subclinical Cushing's disease accompanied by malignant hypertension and diabetes mellitus. (3/47)

A 53-year-old woman was admitted because of hypertension and diabetes mellitus. Elevated diastolic blood pressure, hypertensive retinopathy and renal dysfunction indicated malignant hypertension. Adrenocorticotropic hormone (ACTH) and cortisol levels were high although there were no Cushingoid features. One mg dexamethasone administration decreased neither ACTH nor cortisol levels. Brain magnetic resonance imaging revealed a left pituitary tumor (7 mm x 6 mm). Upon removal, the tumor showed positive ACTH staining by immnohistochemistry, and was diagnosed as pituitary ACTH-secreting adenoma (Cushing's disease). Her blood pressure, renal function, blood glucose and hormone levels subsequently improved. Malignant hypertension and deteriorated diabetes mellitus may have been due to subclinical Cushing's disease.  (+info)

Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma. (4/47)

Both chromophobe carcinoma and sarcomatoid carcinoma of the kidney are rare. The former is characterized by a relatively good prognosis, while the latter is a highly aggressive tumor. Coexistence of the two components in one renal tumor, which has been reported only rarely, is therefore paradoxical. Both sarcomatoid and chromophobe renal carcinoma were diagnosed in a 52-year-old woman following nephrectomy and resection of metastases in the right lobe of the liver. She died of the disease two months after the first operation; only the sarcomatoid component of her tumor was seen in the liver metastasis and the recurrent carcinoma. Differences in phenotype, immunophenotype and DNA-ploidy patterns of the two components are reported. The intensive p53 staining observed only in the sarcomatoid area supports the role of the TP53 gene in the transformation of chromophobe renal carcinoma to sarcomatoid carcinoma.  (+info)

Moyamoya disease associated with pituitary adenoma--report of two cases. (5/47)

Moyamoya disease associated with prolactin (PRL)-producing pituitary adenomas occurred in two females with elevated blood PRL levels (285 and 120 ng/ml). Computed tomography revealed cystic tumors extending from the sella turcica to the suprasellar cistern. Carotid angiography demonstrated stenoses or obstructions of the bilateral internal carotid arteries at their end point and development of bilateral basal moyamoya vessels. Histological diagnosis in one case was PRL-producing chromophobe adenoma. No stigmata of neurofibromatosis or any history of irradiation was found. Compression of carotid arteries by the tumor was unlikely. These cases should therefore be classified as moyamoya disease accompanied by brain tumor, a very rare occurrence. The hypothalamic disturbance caused by moyamoya disease may have induced the hyperprolactinemia, resulting in secondary prolactinoma.  (+info)

Hypopituitarism caused by a melanoma of the pituitary gland. (6/47)

A clinical and pathological description is given of a case of panhypopituitarism caused by a melanoma of the pituitary gland. The possible origins of a melanoma in this site are discussed.  (+info)

Stroke after pituitary irradiation. (7/47)

BACKGROUND AND PURPOSE: Cranial irradiation may lead to accelerated atherosclerosis over several years. Stroke has been described after cranial irradiation administered for a number of conditions. However, pituitary irradiation has only rarely been associated with stroke. CASE DESCRIPTIONS: Two patients, 39 and 46 years of age, suffered strokes 13 and 20 years, respectively, after irradiation for pituitary tumors. Strokes were in the territories of small perforating arteries, but large vessels such as the carotid siphon and anterior cerebral arteries were also abnormal. Other risk factors for stroke were absent. CONCLUSIONS: It is suggested that pituitary irradiation increases the risk of subsequent stroke due to the known effects of ionizing radiation on vascular walls.  (+info)

Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. (8/47)

BACKGROUND: Prognostic markers for renal cell carcinoma (RCC), such as patient symptoms, tumor stage, tumor size, and tumor grade, are useful for determining appropriate follow-up and selecting patients for adjuvant therapy. Histologic coagulative tumor necrosis, also reported to be a prognostic marker for RCC, has not previously been extensively described or investigated. Hence, the objective of the current study was to characterize tumor necrosis as a prognostic feature of RCC. METHODS: The authors of the current study identified 3009 patients treated surgically for RCC between 1970 and 2002 from the Mayo Clinic Nephrectomy Registry (Rochester, MN). Associations of tumor necrosis with clinical, laboratory, and pathologic features were examined with chi-square, Fisher exact test, and Wilcoxon rank-sum tests. Cancer-specific survival was estimated with the Kaplan-Meier method, and associations with outcome were assessed with Cox proportional hazard models. RESULTS: Tumor necrosis was present in 690 of 2445 (28%) clear cell, 196 of 421 (47%) papillary, and 28 of 143 (20%) chromophobe RCCs. The risk ratio for death from RCC in patients with necrotic compared with non-necrotic tumors was 5.27 (95% confidence interval [CI]: 4.56-6.09; P < 0.001) for clear cell, 4.20 (CI: 1.65-10.68; P < 0.001) for chromophobe, and 1.49 (CI: 0.81-2.74; P = 0.199) for papillary RCC. The survival difference for clear cell RCC persisted even after multivariate adjustment for tumor stage, size, and grade (risk ratio 1.90; P < 0.001). CONCLUSIONS: Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC, and it should be routinely reported and used in clinical assessment.  (+info)

Re: Hales method for colloidal ironRe: Hale's method for colloidal iron
Diana Goodwin, HT in Trenton, New Jersey asks: >>Does anyone have a copy of Hales method for colloidal iron? My pathologist has asked for it specifically, probably because it is cited in the literature for differentiation of chromophobe RCC.<< (Bryan Llewellyn has already posted a method as I send this.) The fairly recently described chromophobe variant of renal cell carcinoma (Ive seen them in study slide sets, but never one on the hoof) indeed is supposed to mark very strongly with colloidal iron. Nothing Ive read mentioned any specific technique. Apparently colloidal iron is really useful for distinguishing this uncommon variant of a common cancer. Its called chromophobe because it looks like the chromophobe adenoma of the anterior pituitary. Bob Richmond Samurai Pathologist Knoxville TN ...
Womens Healthcare - Bayer - Bayer Zydus PharmaWomen's Healthcare - Bayer - Bayer Zydus Pharma
In Females: HMG is used in a sequential manner in conjunction with HCG for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of anovulation is functional (secondary to pituitary insufficiency) and is not due to primary ovarian failure. HMG and HCG may also be used to stimulate the development of multiple follicles in ovulatory patients participating in an in-vitro fertilization program. In Males: HMG is used in conjunction with HCG to stimulate spermatogenesis in primary hypogonadotropic hypogonadism (resulting from hypophysectomy, craniopharyngioma, cerebral aneurysm or chromophobe adenoma ...
Neurology MedicineNeurology Medicine
PITUITARY CHROMOPHOBE ADENOMAS NEUROLOGY METABOLISM THERAPY. NY 1953 first edition. Springer. Hardcover octavo. 282pp. Owner signed. VG in Good DJ, dj toned and worn. . ...
Chromophobe cell - WikipediaChromophobe cell - Wikipedia
A chromophobe is a histological structure that does not stain readily, and thus appears relatively pale under the microscope. Chromophobe cells are one of three cell types, the others being basophils and acidophils. One type of chromophobe cell is known as amphophils. Amphophils are epithelial cells found in the anterior and intermediate lobes of the pituitary. Together, these epithelial cells are responsible for producing the hormones of the anterior pituitary and releasing them into the bloodstream. Melanotrophs (also, Melanotropes) are another type of chromophobe which secrete melanocyte stimulating hormone (MSH). "Chromophobe" also refers to a type of renal cell carcinoma (distinct from "clear cell"). Chromophobe renal cancer is part of a rare, genetic disorder known as Birt-Hogg-Dubé syndrome. While renal cell carcinoma is one of the most frequently diagnosed cancers, chromophobe renal cancer only accounts for five percent of renal cancer cases. Furthermore, 30% of patients with ...
Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth | SpringerLinkNonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth | SpringerLink
The postoperative biological behavior of nonfunctioning pituitary adenomas (NFPAs) is variable. Some residual NFPAs are stable long-term, others grow, and
Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised...Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised...
In 1970 a 20 year old woman presented with a pituitary chromophobe adenoma for which she underwent transfrontal pituitary surgery. In 1978 she had to be reoperated on because of local tumour recurrence, resulting in hypopituitarism. Bromocriptine (5 mg/day) was given for 15 years, but the plasma prolactin levels remained elevated. In 2000 the patient presented with signs and symptoms suggestive of a spinal cord lesion at the mid-thoracic level. A magnetic resonance imaging (MRI) scan showed an extensive leptomeningeal mass extending from the brainstem to L5, with a thoracic syringomyelia at the T7-T8 level. The plasma prolactin level was very high (5114 microg/l). A biopsy showed the presence of a metastasised prolactinoma.On administration of high dose cabergoline, 0.5 mg twice a day orally, the plasma prolactin levels decreased within one month and then normalised within 26 months. Tumour load reduced considerably but unfortunately, her signs and symptoms did not improve. This case illustrates ...
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes - Nuffield Department of Population HealthMacroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes - Nuffield Department of Population Health
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma,...Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma,...
Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Childhood Central Nervous System Germinoma Childhood Central Nervous System Mixed Germ Cell Tumor Childhood Central Nervous System Teratoma Childhood Central Nervous System Yolk Sac Tumor Childhood Choroid Plexus Tumor Childhood Craniopharyngioma Childhood Ependymoblastoma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood Infratentorial Ependymoma Childhood Medulloepithelioma Childhood Mixed Glioma Childhood Oligodendroglioma Childhood Supratentorial Ependymoma Gonadotroph Adenoma Pituitary Basophilic Adenoma Pituitary Chromophobe Adenoma Pituitary Eosinophilic Adenoma Prolactin Secreting Adenoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Anaplastic Large Cell Lymphoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Central Nervous System Embryonal Tumor Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood ...
Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomasClinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas
Most patients with pituitary adenomas present with signs and symptoms of hormone hypersecretion (eg, hyperprolactinemia, growth hormone [GH] excess, or hypercortisolism). However, 25 to 30 percent of pituitary adenomas are clinically nonfunctioning o
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors -...Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors -...
To describe baseline calcitriol/PTH status in patients with uncontrolled acromegaly, with subanalyses based on presence of hyperprolactinemia.. To assess the change in calcitriol/PTH levels after treatment with acromegaly, with subanalyses based on type of therapy (surgical or medical).. To evaluate the calcium and calcitriol/PTH levels in patients with acromegaly compared to patients with nonfunctioning pituitary adenomas, with subanalyses based on presence of hyperprolactinemia in either group. ...
RCC Chromophobe | Cancer Survivors NetworkRCC Chromophobe | Cancer Survivors Network
Liz, I guess you can easily look up the stats in various places for general information e.g. here: http://www.cancer.gov/statistics/find Roughly, it looks this way - kidney cancer is one of the less frequent cancers. Figures in the US and UK are fairly similar and for 2009, in the UK Kidney cancer is the eighth most common cancer in the UK (2009), accounting for around 3% of all new cases. It is the sixth most common cancer among men in the UK (2009), accounting for more than 3% of all new cases of cancer in males. It is the ninth most common cancer among women in the UK (2009), responsible for more than 2% of all new cases of cancer in females.. In both the US and Europe, chromophobe RCC accounts for only about one in twenty cases of RCC. So, on the above figures, You could reckon that chromophobe RCC would account for around 0.15% of cancer cases in men and 0.1% of cancer cases in women. This needs to be tweaked just a little because although kidney cancer is more common in males than in ...
nonfunctioning pituitary tumor drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginenonfunctioning pituitary tumor drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
MeSH-minor] Acromegaly / drug therapy. Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Aged. Carcinoma / radionuclide imaging. Humans. Indium Radioisotopes / therapeutic use. Insulin-Like Growth Factor I / secretion. Kidney Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Middle Aged. Pheochromocytoma / radionuclide imaging. Predictive Value of Tests. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Sensitivity and Specificity. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / secretion. Treatment ...
A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide TreatmentA Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
Case Reports in Endocrinology is a peer-reviewed, Open Access journal that publishes case reports related to the endocrine system and its associated diseases.
ITS BEEN AWHILE | Cancer Survivors NetworkIT'S BEEN AWHILE | Cancer Survivors Network
Hello eveyone,. Its been awhile since Ive posted on here. I pop in every once in awhile. But today Im looking for a little information. If you know my story. I have had partial neph been one year NED. My son too had RCC this past year. He had total neph. Both of us stage 3. But he was clear cell, me chromophobe (in the middle of a second opinion from my original pathology report; geneticist recommended). Anyways, Thank God I convinced my son to go across the street to MDAnderson for follow up care. He has done genetic testing (no genetic markers) and he is part of their kidney cancer research. This [ast week he finally has had the baseline scans done. The oncologist says things look good but there is some soft tissue near where they did the neph. She says it looks like normal scarring from the radical but they want to watch it for awhile. Has anyone ever had a similiar situation? He had his full neph in November. Hes feeling a bit down because he realized today that he will not feel free from ...
Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor?<...Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor?<...
TY - JOUR. T1 - Silent corticotroph adenoma with multiple cysts. T2 - Pars intermedia tumor?. AU - Nishioka, Hiroshi. AU - Hirano, Asao. AU - Asa, Sylvia L.. PY - 1992/3. Y1 - 1992/3. N2 - A silent corticotroph adenoma with multiple cysts was found incidentally at autopsy. By immunohistochemistry, most of the adenoma cells contained reactivity for adrenocorticotropic hormone and beta-endorphin; a few cells stained for beta-subunit of luteinizing hormone. The cysts, interspersed within the tumor, were lined by cuboidal epithelium with foci of stratified squamous epithelium. The lining cells contained immunoreactive keratin; some cells were positive for S-100 protein or glial fibrillary acidic protein, and a few cells were also immuno-stained for adrenocorticotropic hormone and beta-endorphin. It is suggested that this tumor may represent a neoplasm of pars intermedia derivation.. AB - A silent corticotroph adenoma with multiple cysts was found incidentally at autopsy. By immunohistochemistry, ...
Browse In Striae, Immunostaining, Immunohistochemistry | EDM Case ReportsBrowse In Striae, Immunostaining, Immunohistochemistry | EDM Case Reports
Silent corticotroph adenoma (SCA) is an unusual type of nonfunctioning pituitary adenoma (NFA) that is silent both clinically and biochemically and can only be recognized by positive immunostaining for ACTH. Under rare circumstances, it can transform into hormonally active disease presenting with severe Cushing syndrome. It might often produce diagnostic dilemma with difficult management issue if not thoroughly investigated and subtyped accordingly following surgery. Here, we present a 21-year-old male who initially underwent pituitary adenomectomy for presumed NFA with compressive symptoms. However, he developed recurrent and invasive macroadenoma with severe clinical as well as biochemical hypercortisolism during post-surgical follow-up. Repeat pituitary surgery was carried out urgently as there was significant optic chiasmal compression. Immunohistochemical analysis of the tumor tissue obtained on repeat surgery proved it to be an aggressive corticotroph adenoma. Though not cured, he showed ...
A mutation and expression analysis of the oncogene BRAF in pituitary adenomas | Archivio Istituzionale della RicercaA mutation and expression analysis of the oncogene BRAF in pituitary adenomas | Archivio Istituzionale della Ricerca
OBJECTIVE: BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carcinomas, usually at position V600E that leads to constitutive activity in the Ras-mitogen-activated protein kinase (MAPK) pathway. We speculated that this same gene may be either mutated at this site, or overexpressed, in pituitary adenomas. DESIGN AND MEASUREMENTS: We sequenced 37 pituitary adenomas for a mutation at the V600E position. In addition, we investigated B-Raf mRNA expression in normal pituitary (n = 5) and nonfunctioning pituitary adenomas (NFPA) (n = 6) by semiquantitative PCR, and in a further 27 pituitary adenomas of various types and 10 normal pituitaries using real-time quantitative PCR. Finally, we explored B-Raf protein expression in 10 normal pituitaries and 12 NFPAs. RESULTS: No sequence mutations for the substitution V600E were identified. B-Raf mRNA was overexpressed in pituitary adenomas compared to normal pituitary, and this was entirely due to overexpression in NFPAs. ...
JCM | Free Full-Text | Results of Treatment with Modern Fractionated Radiotherapy, Contemporary Stereotactic Radiosurgery, and...JCM | Free Full-Text | Results of Treatment with Modern Fractionated Radiotherapy, Contemporary Stereotactic Radiosurgery, and...
Background: To compare the effects of contemporary stereotactic radiosurgery (SRS), modern fractionated radiotherapy (FRT), and transsphenoidal surgery on nonfunctioning pituitary macroadenoma. Methods: We enrolled patients with nonfunctioning pituitary macroadenoma. To compare treatment outcomes, the patients were categorized into three groups according to the treatment modality: group 1, patients receiving modern FRT; group 2, patients receiving contemporary SRS; and group 3, patients receiving transsphenoidal surgery. Results: In total, 548 patients with nonfunctioning pituitary macroadenoma were selected for our study. Univariate and multivariate Cox regression analysis results indicated that the treatment modalities were significant independent prognostic factors. In multivariable Cox proportional hazard regression analysis, the adjusted hazard ratios (aHR; 95% confidence interval (CI)) of local recurrence were 0.27 (0.10–0.91) and 1.95 (1.25–2.37) for the SRS and transsphenoidal
Preoperative renal tumor subtype differentiation is definitely important for radiology and - Comparison of the Cancer Gene...Preoperative renal tumor subtype differentiation is definitely important for radiology and - Comparison of the Cancer Gene...
Preoperative renal tumor subtype differentiation is definitely important for radiology and urology in clinical practice. vs 40.3180.4833 vs 50.0130.1654 vs 5 0.0010.411 Open in a separate window Note: 1: clear cell renal cell carcinoma; 2: papillary renal cell carcinoma; 3: chromophobic renal cell carcinoma; 4: uroepithelial carcinoma; 5: fat-poor angiomyolipoma. Open in a separate window Figure 3 Box-and-whisker plot of em K /em trans value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em K /em trans, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor angiomyolipoma. Open in a separate window Figure 4 Box-and-whisker plot of em V /em e value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em V /em e, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor ...
Gene expression changes in subcutaneous adipose tissue due to Cushings disease. | mrc2Gene expression changes in subcutaneous adipose tissue due to Cushing's disease. | mrc2
Glucocorticoids have major effects on adipose tissue metabolism. To study tissue mRNA expression changes induced by chronic elevated endogenous glucocorticoids, we performed RNA sequencing on the subcutaneous adipose tissue from patients with Cushings disease (n=5) compared to patients with nonfunctioning pituitary adenomas (n=11). We found a higher expression of transcripts involved in several metabolic pathways, including lipogenesis, proteolysis and glucose oxidation as well as a decreased expression of transcripts involved in inflammation and protein synthesis. To further study this in a model system, we subjected mice to dexamethasone treatment for 12 weeks and analyzed their inguinal (subcutaneous) fat pads, which led to similar findings. Additionally, mice treated with dexamethasone showed drastic decreases in lean body mass as well as increased fat mass, further supporting the human transcriptomic data. These data provide insight to transcriptional changes that may be responsible for ...
Corneal and lenticular pigmentation following long term chlorpromazine therapy and its significance in causing visual defects. ...Corneal and lenticular pigmentation following long term chlorpromazine therapy and its significance in causing visual defects. ...
INTRODUCTION: For a clear image to be formed on the retina, the transparency of cornea and lens is essential. Cornea contributes to two-thirds of refractive power and lens to one- third of refractive power. In the visible range of spectrum (380 to 760 nm), the cornea transmits almost 100% of light energy. AIM OF THE STUDY: 1) To evaluate the incidence of lenticular and corneal pigmentation with dose and duration of chlorpromazine therapy. 2 To evaluate the significance of lenticular and corneal pigmentation in causing visual defects . MATERIALS AND METHODS: This clinical study was done to evaluate the incidence of corneal and lenticular pigmentation in patients with long term chlorpromazine therapy and its significance in causing visual defects. The study design was a cross-sectional study conducted in Institute of Mental Health , Ayanavaram, Chennai. The patients included in this study were in-patients residing in the Institute of Mental Health . A total of 100 patients, 50 males and 50 female ...
Renal (Kidney) CancerRenal (Kidney) Cancer
The Chromophobe (ChRCC) type renal cell cancer is rare and behaves differently than the more common renal cell carcinoma. Consequently it has not been extensively studied. Unfortunately, there are no proven treatments for the metastatic disease and the many drugs that have been approved for clear cell cancer do not work well for this subtype. At one time chemotherapy was thought to be effective but studies did not confirm it. Overexpression of. Read more ...
Surface Inspection Software | Cognex Corp. | New Products | Apr 2010 | Photonics SpectraSurface Inspection Software | Cognex Corp. | New Products | Apr 2010 | Photonics Spectra
!%Cognex Corp.%! has released VisionPro Surface, a vision software package for inspecting the surface of materials. It combines new visual defect det
Strabismus - Pathways.orgStrabismus - Pathways.org
A visual defect in which both eyes cannot focus together on an object because of an imbalance of the eye muscles, leading to squinting or crossed eyes.. ...
Chromophobe renal cell carcinoma with sarcomatoid differentiation<...Chromophobe renal cell carcinoma with sarcomatoid differentiation<...
TY - JOUR. T1 - Chromophobe renal cell carcinoma with sarcomatoid differentiation. AU - Lauer, Scott R.. AU - Zhou, Ming. AU - Master, Viraj A.. AU - Osunkoya, Adeboye O.. PY - 2013/4/1. Y1 - 2013/4/1. N2 - OBJECTIVE: To investigate the clinicopathologic features of chromophobe renal cell carcinoma with sarcomatoid differentiation. STUDY DESIGN: A search was made through the surgical pathology and expert consult files of two major academic institutions from 2003 to 2011 for cases of chromophobe renal cell carcinoma with sarcomatoid differentiation. RESULTS: Fourteen patients were identified. The patients included 9 males (64%) and 5 females (36%). The mean patient age was 60.4 years (range, 40-82 years). There was a left-sided predominance: left (9 patients) and right (5 patients). The mean tumor size was 14.6 cm (range, 9.5-28.0 cm), and the mean percentage sarcomatoid differentiation was 67% (range, 30-99%). All tumors exhibited moderate to extensive areas of necrosis. The nonsarcomatoid ...
Chromophobe renal cell carcinomaChromophobe renal cell carcinoma
... is a rare type of kidney cancer that develops in cells that are involved in the production of urine. Cancers form when a change (mutation) in DNA causes certain cells to grow out of control, sometimes forming a lump or a tumor. Some of these cancerous cells can break off and spread to other parts of the body where they will continue to grow (metastasis). Chromophobe renal cell carcinoma usually occurs in adults between the ages of 40 and 60, although it can appear in all age groups. This type of carcinoma is associated with Birt-Hogg-Dubé syndrome, an inherited disorder caused by a mutation in the FLCN gene. The FLCN gene is involved in regulating cell growth, and a mutation in this gene can cause cells to grow out of control. This situation places affected individuals at higher risk of developing chromophobe renal cell carcinoma as well as noncancerous growths in the kidneys, lungs, and hair follicles. Common symptoms include the presence of blood in the urine, ...
Chromophobe renal cell carcinomaChromophobe renal cell carcinoma
... is a rare type of kidney cancer that develops in cells that are involved in the production of urine. Cancers form when a change (mutation) in DNA causes certain cells to grow out of control, sometimes forming a lump or a tumor. Some of these cancerous cells can break off and spread to other parts of the body where they will continue to grow (metastasis). Chromophobe renal cell carcinoma usually occurs in adults between the ages of 40 and 60, although it can appear in all age groups. This type of carcinoma is associated with Birt-Hogg-Dubé syndrome, an inherited disorder caused by a mutation in the FLCN gene. The FLCN gene is involved in regulating cell growth, and a mutation in this gene can cause cells to grow out of control. This situation places affected individuals at higher risk of developing chromophobe renal cell carcinoma as well as noncancerous growths in the kidneys, lungs, and hair follicles. Common symptoms include the presence of blood in the urine, ...
Comprehensive review of visual defects reported with topiramate | OPTHComprehensive review of visual defects reported with topiramate | OPTH
Comprehensive review of visual defects reported with topiramate Lisa Ford,1 Jeffrey L Goldberg,2 Fred Selan,1 Howard E Greenberg,1 Yingqi Shi1 1Janssen Research & Development, LLC, Titusville, NJ, 2Byers Eye Institute, Stanford University, Palo Alto, CA, USA Objective: The objective of this study was to analyze clinical patterns of visual field defects (VFDs) reported with topiramate treatment and assess possible mechanism of action (MOA) for antiepileptic drug (AED) associated VFDs.Methods: A comprehensive topiramate database review included preclinical data, sponsor’s clinical trials database, postmarketing spontaneous reports, and medical literature. All treatment-emergent adverse events (TEAEs) suggestive of retinal dysfunction/damage were summarized. Relative risk (RR) was computed from topiramate double-blind, placebo-controlled trials (DBPCTs) data.Results: Preclinical studies and medical literature review suggested that despite sharing gamma-aminobutyric acid (GABA)-ergic MOA with
Chromophobe renal cell carcinoma Datasets | BioGPSChromophobe renal cell carcinoma Datasets | BioGPS
Datasets are collections of data. BioGPS has thousands of datasets available for browsing and which can be easily viewed in our interactive data chart. Learn more.. ...
Neil Alouch, MD | Office of the President | Creighton UniversityNeil Alouch, MD | Office of the President | Creighton University
Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0304-y. [Epub ahead of print] PubMed PMID: 31231128 ...
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report | Journal of Medical Case Reports |...Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report | Journal of Medical Case Reports |...
RCC treatment has been classically derived from clinical trials that incorporated all histologies comprising clear cell, papillary, chromophobe, and other rarer subtypes. Most recently, novel therapies (sunitinib and sorafenib) have shown significant clinical activity in advanced RCC and have changed the standard of care in this disease [1-3]. However, pivotal studies with these drugs were performed exclusively in patients with clear cell histology. Therefore, the optimal therapy for papillary and chromophobe histologies remains unknown. Overall, ChRCC is considered to portend a good prognosis and is associated with earlier-stage tumors and longer overall survival in comparison with CCRCC. There are conflicting reports on prognosis in metastatic disease, and few data on response to treatment exist. Increased VEGF-6 and c-Kit (i.e., mast/stem cell growth factor receptor; proto-oncogene c-Kit; tyrosine-protein kinase Kit; or CD117) expressions have been reported in ChRCC, but the relevance of this ...
Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment |...Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment |...
ABSTRACT Objective: To evaluate the preoperative imaging manifestation and therapeutic effect of laparoscopic simple enucleation (SE) for localized chromophobe renal cell carcinoma (chRCC).. Materials and Methods: Clinical data of 36 patients who underwent laparoscopic SE of localized chRCC at our institute were retrospectively analyzed. All patients underwent preoperative renal protocol CT (unenhanced, arterial, venous, and delayed images). CT scan characteristics were evaluated. After intraoperative occlusion of the renal artery, the tumor was free bluntly along the pseudocapsule and enucleated totally. The patients were followed up regularly after the operation.. Results: Mean tumor diameter was 3.9±1.0 cm, 80% of tumors were homogeneous and all the tumors had complete pseudocapsule. The attenuation values were slightly lower than normal renal cortex and degree of enhancement of the tumors were significantly lower than normal renal cortex. Mean operation time was 104.3±18.2 min. Mean warm ...
Oncology Times Supplement October 25, 2016 Page 12Oncology Times Supplement October 25, 2016 Page 12
METASTATIC CHROMOPHOBE RCC continued from page 11 chromophobe RCC. The rest had clear cell mRCC. Overall and progression-free survival rates; time to treatment failure; overall, par-tial, and complete response rates; and stable and progressive disease were calculated. fi ed in low, intermediate, and high risk," remarked Yip. "When combined, all these factors we uncovered had an appropriate refl ection in stratifying just like wed see in clear cell RCCs." In this study, patients with IMDC fa-vorable criteria (18%) had median overall survival of 31.4 months. Those with in-termediate risk (59%) achieved an over-all survival of 27.3 months, and poor risk patients (23%) had overall survival of 4.8 months. "In the past, we didnt have a clear understanding of whether this treatment was applicable to such a rare subtype. Now… we can tell our patients in clinic that theres good grounded evidence for why we can treat them similarly to how we would patients with clear cell RCC." Evaluating Outcomes ...
Pituitary Tumors - Causes, Symptoms, Diagnosis, TreatmentPituitary Tumors - Causes, Symptoms, Diagnosis, Treatment
How do pituitary tumors affect you and what are the risks, symptoms and causes of pituitary tumors? Read on how pituitary tumors affect the quality of your life and just how effective is treatment.
Pituitary Tumors Resources - Navigating CarePituitary Tumors Resources - Navigating Care
What is Pituitary Tumors? Get the facts about Pituitary Tumors symptoms, testing, treatment and care options from trusted sources.
Galactorrhea (Aftercare Instructions) - What You Need to KnowGalactorrhea (Aftercare Instructions) - What You Need to Know
Care guide for Galactorrhea (Aftercare Instructions). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Cranial Nerve Testing | almostadoctorCranial Nerve Testing | almostadoctor
Snellen Test - ask them to stand at 6 metres (measure it out if you need to) and read out the lowest set of letters they can see. In a traditional test, there will be 11 rows of letters, the row with 8th row being the smallest a person with 6/6 vision can read. The biggest letters represent 6/60 vision. Often a smaller 3m Snellen test is used on the ward due to lack of space! Patients should wear their normal glasses - if they have any. You are not an optician - just looking for any serious visual defects! Make sure to test one eye at a time! - ask the patient to cover their eye; just asking them to close it isnt good enough (as it can be difficult for patient,s and they may partially close the eye you are assessing, which obviously has implications for your results ...
What is the treatment for a Pituitary Tumour? | Pituitary TumorsWhat is the treatment for a Pituitary Tumour? | Pituitary Tumors
The pea sized structure attached to the undersurface of your brain with the help of a thin stalk, and a tumor that develops in here can be dangerous, find out the symptoms.
After 9 months - AF arrives | DailyStrengthAfter 9 months - AF arrives | DailyStrength
Happy Monday All! Heres a quick recap of my situation. I havent had a visit from AF in 9 months. After the 1st 3 we discovered a pituitary tumor, once that...
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas<...Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas<...
TY - JOUR. T1 - Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. AU - Ioachimescu, Adriana G.. AU - Fleseriu, Maria. AU - Hoffman, Andrew R.. AU - Vaughan, T. Brooks. AU - Katznelson, Laurence. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs psychological side effects, either de novo or as exacerbations of prior psychiatric disease. Methods: Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Case series and case reports of psychiatric complications were also reviewed. Results: Most studies were cross-sectional and had a control group of healthy volunteers or patients with nonfunctioning pituitary adenomas. There were few prospective ...
Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas<...Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas<...
TY - JOUR. T1 - Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas. AU - Lim, Jung Soo. AU - Lee, Mi Kyung. AU - Choi, Eunhee. AU - Hong, Namki. AU - Il Jee, Soo. AU - Kim, Sun Ho. AU - Lee, Eun Jig. PY - 2019/4/1. Y1 - 2019/4/1. N2 - Purpose: The molecular mechanisms underlying tumor growth in Cushings disease (CD) still remain a challenge. Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified. We investigated the association between the expression of cellular markers regarding pituitary tumor progression and initial or postoperative hormone levels in patients with CD. Methods: Tumor tissues from 28 corticotroph adenomas (female 26, male 2, mean age 39.21 ± 10.39 years) were subject to immunohistochemical study using the following antibodies: pituitary tumor-transforming ...
ORBi: Browsing ORBiORBi: Browsing ORBi
in Endocrine Reviews (2013). Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their ... [more ▼]. Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their management involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist. Recent years have seen two separate, complimentary advances in inherited pituitary tumor research. The clinical condition of familial isolated pituitary adenomas (FIPA) has been described, which encompasses the familial occurrence of isolated pituitary adenomas outside of the setting of syndromic conditions like multiple ...
Pituitary TumoursPituitary Tumours
... (pituitary adenomas) are tumours that form in the pituitary gland, which is located at the base of the brain, behind the nose.
Galactorrhea | Memorial HospitalGalactorrhea | Memorial Hospital
Learn more about Galactorrhea at Memorial Hospital DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Pituitary adenoma symptoms and treatmentPituitary adenoma symptoms and treatment
A pituitary adenoma is a brain tumour that is usually classified as benign and can usually be easily removed. Learn more about it here!
Pituitary AdenomasPituitary Adenomas
... , incidence, etiology, pathological anatomy, clinical manifestations, diagnosis, hormonal studies, surgical treatment, standard and modified approaches, indications for surgical treatment, a trial for constructing protocols for treatment strategies and postoperative results and complications.
Pituitary Adenoma | Osceola Regional Medical CenterPituitary Adenoma | Osceola Regional Medical Center
Learn more about Pituitary Adenoma at Osceola Regional Medical Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
List of Pituitary Tumor Medications - Drugs.comList of Pituitary Tumor Medications - Drugs.com
Compare risks and benefits of common medications used for Pituitary Tumor. Find the most popular drugs, view ratings, user reviews, and more...
Adenoma - secretingAdenoma - secreting
Medical information, Adenoma - secreting. Definition of Adenoma - secreting, symptoms of Adenoma - secreting, treatment of Adenoma - secreting, and prevention of Adenoma - secreting. Exams and Tests Adenoma - secreting.
CAPITAL: CAre for PITuitary Adenoma Leiden 8-9/6/2017 - ΩΡΛCAPITAL: CAre for PITuitary Adenoma Leiden 8-9/6/2017 - ΩΡΛ
Γραμματεία Κα Βάσω Ντόντου,. Νοσοκομείο Υγεία,. καθημερινά 8πμ - 3μμ,. τηλ 210-6867321 6956290928. ...
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Adenoma, ChromophobeAdenomaAdenoma, OxyphilicKidney NeoplasmsCarcinoma, Renal CellPituitary NeoplasmsKeratin-7Adenoma, PleomorphicAdenoma, VillousAdenocarcinoma, Clear CellCalbindin 1Carcinoma, PapillaryMyelin and Lymphocyte-Associated Proteolipid ProteinsAdrenocortical AdenomaAdenoma, Liver CellBirt-Hogg-Dube SyndromeParvalbuminsImmunohistochemistryNephrectomyChromosomes, Human, Pair 10Tumor Markers, BiologicalAdaptor Protein Complex mu SubunitsChromosomes, Human, Pair 1Ossification, HeterotopicChromosomes, Human, Pair 2Growth Hormone-Secreting Pituitary AdenomaColorectal NeoplasmsColonic PolypsACTH-Secreting Pituitary AdenomaAdaptor Protein Complex 1Keratin-20In Situ Hybridization, FluorescenceChromosomes, Human, Pair 6NeprilysinTissue Array AnalysisAdenoma, AcidophilColonoscopyAdenomatous PolypsCalbindinsProlactinomaKidneyChromosomes, Human, Pair 17Adenoma, BasophilChromosome AberrationsAdrenal Cortex NeoplasmsKeratinsOligonucleotide Array Sequence AnalysisGene Expression ProfilingDNA, NeoplasmGene Expression Regulation, NeoplasticReverse Transcriptase Polymerase Chain ReactionImmunoenzyme TechniquesAdenomatous Polyposis ColiNeoplasm ProteinsAcromegalyCushing SyndromeGenes, APCRNA, MessengerPrognosisMembrane ProteinsHyperparathyroidismSalivary Gland NeoplasmsColonic NeoplasmsIntestinal NeoplasmsHyperplasiaNeoplasms, Multiple PrimaryAdrenal Gland NeoplasmsPituitary ACTH HypersecretionParotid NeoplasmsCarcinomaHyperaldosteronismSphenoid BoneDuodenal NeoplasmsAdrenocorticotropic HormonePituitary GlandAdenocarcinomaHyperparathyroidism, PrimaryThyroid NeoplasmsPrecancerous ConditionsSella TurcicaSigmoidoscopy
List of MeSH codes (C04)List of MeSH codes (C04)
... adenoma, bile duct MeSH C04.557.470.035.095 --- adenoma, chromophobe MeSH C04.557.470.035.100 --- adenoma, islet cell MeSH ... adenoma, acidophil MeSH C04.557.465.625.650.075 --- adenoma, basophil MeSH C04.557.465.625.650.095 --- adenoma, chromophobe ... adenoma, acidophil MeSH C04.557.580.625.650.075 --- adenoma, basophil MeSH C04.557.580.625.650.095 --- adenoma, chromophobe ... adenoma MeSH C04.557.470.035.012 --- acth-secreting pituitary adenoma MeSH C04.557.470.035.025 --- adenoma, acidophil MeSH ...
International Classification of Diseases for OncologyInternational Classification of Diseases for Oncology
M8270/0 Chromophobe adenoma (C75.1) M8270/3 Chromophobe carcinoma (C75.1) Chromophobe adenocarcinoma (M8271/0) Prolactinoma ( ... Black adenoma Pigmented adenoma M8373/0 Adrenal cortical adenoma, clear cell (C74.0) M8374/0 Adrenal cortical adenoma, ... Oxyphilic adenoma Oncocytic adenoma Oncocytoma Hurthle cell adenoma(C73.9) Hurthle cell tumor Follicular adenoma, oxyphilic ... NOS Pick tubular adenoma Sertoli cell adenoma Tubular androblastoma, NOS Testicular adenoma M8640/3 Sertoli cell carcinoma (C62 ...
Cancer syndromeCancer syndrome
Tumors with increased risk in this disorder are colorectal cancer, gastric adenomas and duodenal adenomas. Nevoid basal cell ... renal cell carcinoma of chromophobe, hybrid oncocytic, or oncocytoma histology; sebaceous carcinoma; and sex cord tumors with ... An individual with this disease will have hundreds to thousands of benign adenomas throughout their colon, which will in most ... Other tumors increased in frequency include; osteomas, adrenal adenomas and carcinomas, thyroid tumors and desmoid tumors. The ...
Birt-Hogg-Dubé syndromeBirt-Hogg-Dubé syndrome
Hybrid oncocytoma/chromophobe carcinoma, found in 50% of cases, is the most commonly found cancer, followed by chromophobe ... parathyroid adenomas, flecked chorioretinopathy, neurothekeoma, meningiomas, angiofibromas of the face, trichoblastomas, ... Renal tumors can manifest as multiple types of renal cell carcinoma, but certain pathological subtypes (including chromophobe, ... chromophobe renal cell carcinoma and renal oncocytoma. BHD-associated tumorigenesis differs between the kidney, where loss of ...
Anterior pituitaryAnterior pituitary
A third type of pituitary adenoma secretes excess ACTH, which in turn, causes an excess of cortisol to be secreted and is the ... The pars distalis contains two types of cells including chromophobe cells and chromophil cells. The chromophils can be further ... This hypersecretion often results in the formation of a pituitary adenoma (tumour), which are benign apart from a tiny fraction ... Tropic hormones Pituitary adenoma Triple bolus test Posterior pituitary Hypopituitarism Hypothalamic-pituitary-somatic axis ...
List of OMIM disorder codesList of OMIM disorder codes
TCF4 Pituitary adenoma, ACTH-secreting; 219090; AIP Pituitary adenoma, growth hormone-secreting; 102200; AIP Pituitary adenoma ... chromophobe, somatic; 144700; FLCN Renal cell carcinoma; 144700; DIRC2 Renal cell carcinoma; 144700; HNF1A Renal cell carcinoma ... PRKN Adenomas, multiple colorectal; 608456; MUTYH Adenomas, salivary gland pleomorphic; 181030; PLAG1 Adenomatous polyposis ... EIF2B4 Leydig cell adenoma, somatic, with precocious puberty; 176410; LHCGR Leydig cell hypoplasia with hypergonadotropic ...
Lactotropic cellLactotropic cell
... a prolactin-secreting pituitary adenoma. ... Chromophobe cell. Posterior. *Pars nervosa. *Median eminence. * ...
pituitary glandpituitary gland
Pituitary adenomas, noncancerous tumors that occur in the pituitary gland.. All of the functions of the pituitary gland can be ...
ThyroidThyroid
The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck.[64 ... and thyroid adenomas. Malignant nodules, which only occur in about 5% of nodules, include follicular, papillary, medullary ... or from pituitary adenomas which may cause an overproduction of thyroid stimulating hormone.[45] Hyperthyroidism often causes a ... a solitary thyroid adenoma, or inflammation. Other causes include drug-induced excess of iodine, particularly from amiodarone, ...
Adrenal cortexAdrenal cortex
March 2002). "Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro ... "G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism". J. Endocrinol. 195 (1 ...
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Adenoma, ChromophobeAdenomaAdenoma, OxyphilicKidney NeoplasmsCarcinoma, Renal CellPituitary NeoplasmsKeratin-7Adenoma, PleomorphicAdenoma, VillousAdenocarcinoma, Clear CellCalbindin 1Carcinoma, PapillaryMyelin and Lymphocyte-Associated Proteolipid ProteinsAdrenocortical AdenomaAdenoma, Liver CellBirt-Hogg-Dube SyndromeParvalbuminsImmunohistochemistryNephrectomyChromosomes, Human, Pair 10Tumor Markers, BiologicalAdaptor Protein Complex mu SubunitsChromosomes, Human, Pair 1Ossification, HeterotopicChromosomes, Human, Pair 2Growth Hormone-Secreting Pituitary AdenomaColorectal NeoplasmsColonic PolypsACTH-Secreting Pituitary AdenomaAdaptor Protein Complex 1Keratin-20In Situ Hybridization, FluorescenceChromosomes, Human, Pair 6NeprilysinTissue Array AnalysisAdenoma, AcidophilColonoscopyAdenomatous PolypsCalbindinsProlactinomaKidneyChromosomes, Human, Pair 17Adenoma, BasophilChromosome AberrationsAdrenal Cortex NeoplasmsKeratinsOligonucleotide Array Sequence AnalysisGene Expression ProfilingDNA, NeoplasmGene Expression Regulation, NeoplasticReverse Transcriptase Polymerase Chain ReactionImmunoenzyme TechniquesAdenomatous Polyposis ColiNeoplasm ProteinsAcromegalyCushing SyndromeGenes, APCRNA, MessengerPrognosisMembrane ProteinsHyperparathyroidismSalivary Gland NeoplasmsColonic NeoplasmsIntestinal NeoplasmsHyperplasiaNeoplasms, Multiple PrimaryAdrenal Gland NeoplasmsPituitary ACTH HypersecretionParotid NeoplasmsCarcinomaHyperaldosteronismSphenoid BoneDuodenal NeoplasmsAdrenocorticotropic HormonePituitary GlandAdenocarcinomaHyperparathyroidism, PrimaryThyroid NeoplasmsPrecancerous ConditionsSella TurcicaSigmoidoscopy
Chromophobe adenoma | Definition of Chromophobe adenoma at Dictionary.comChromophobe adenoma | Definition of Chromophobe adenoma at Dictionary.com
Chromophobe adenoma definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look ... chromophil adenoma, chromophile, chromophilia, chromophilous, chromophobe, chromophobe adenoma, chromophobe cell, chromophobia ...
dictionary.com
Chromophobe Adenoma disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsChromophobe Adenoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
MalaCards based summary : Chromophobe Adenoma, also known as adenoma, chromophobe, is related to adenoma and galactorrhea. An ... MalaCards organs/tissues related to Chromophobe Adenoma:. 41 Pituitary, T Cells, Thyroid, Ovary, Skin, Testes ... Drugs for Chromophobe Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):. (show all 15) #. Name. ... Articles related to Chromophobe Adenoma:. (show top 50) (show all 95) #. Title. Authors. Year. ...
malacards.org
Tags head + chromophobe adenoma | PEIR Digital LibraryTags head + chromophobe adenoma | PEIR Digital Library
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
peir.path.uab.edu
Chromophobe adenoma: Definition with Chromophobe adenoma Pictures and PhotosChromophobe adenoma: Definition with Chromophobe adenoma Pictures and Photos
Definition of Chromophobe adenoma with photos and pictures, translations, sample usage, and additional links for more ... chromophobe. chromophobe adenoma (current term). chromophobe cells of anterior lobe of hypophysis. chromophobe granules. ... Chromophobe Adenoma Images Lexicographical Neighbors of Chromophobe Adenoma. chromonychia. chromonychias. chromopectic. ... Medical Definition of Chromophobe adenoma. 1. A tumour of the adenohypophysis whose cells do not stain with either acid or ...
lexic.us
Adenoma, ChromophobeAdenoma, Chromophobe
... - 2 Studies Found. Status. Study Terminated. Study Name: Gamma-Secretase Inhibitor RO4929097 in Treating ...
webhealthnetwork.com
Neurology MedicineNeurology Medicine
PITUITARY CHROMOPHOBE ADENOMAS NEUROLOGY METABOLISM THERAPY. NY 1953 first edition. Springer. Hardcover octavo. 282pp. Owner ... PITUITARY CHROMOPHOBE ADENOMAS NEUROLOGY METABOLISM THERAPY. by Nurnberger, John I. and Saul R. Korey. Seller. Xerxesbooks. ...
biblio.com
Vasopressin | biochemistry | Britannica.comVasopressin | biochemistry | Britannica.com
present with chromophobe adenoma* In pituitary tumour. *production in mammals* In neurohormone ...
britannica.com
Hypothyroidism Secondary to Biologically Inactive Thyroid-Stimulating Hormone Secretion by a Pituitary Chromophobe Adenoma:...Hypothyroidism Secondary to Biologically Inactive Thyroid-Stimulating Hormone Secretion by a Pituitary Chromophobe Adenoma:...
... suffering from a large pituitary adenoma and panhypopituitarism, was found to have severely elevated thyrotrophin (thyroid- ... After surgical removal of the pituitary chromophobe adenoma, T4 levels returned to normal (6.8 μg/dL) and TSH levels improved ... Hypothyroidism Secondary to Biologically Inactive Thyroid-Stimulating Hormone Secretion by a Pituitary Chromophobe Adenoma: ... Hypothyroidism Secondary to Biologically Inactive Thyroid-Stimulating Hormone Secretion by a Pituitary Chromophobe Adenoma: ...
jamanetwork.com
Human Reproduction: GlossaryHuman Reproduction: Glossary
Chromophobe adenoma: Adenoma of the pituitary gland, consisting of cells that are neither acidophilic nor basophilic. ... Hypotheses for their origin include reduced pituitary dopamine concentration and/or a vascular isolation of the adenoma cells. ...
library.med.utah.edu
Primary Hypothalamic Lymphoma in an Adult Male: A Case Report and Literature Review. - Free Online LibraryPrimary Hypothalamic Lymphoma in an Adult Male: A Case Report and Literature Review. - Free Online Library
Papanastasiou MRI-pituitary adenoma Chromophobe pituitary et al. (21) 2012 with inhomogeneous adenoma. Diffuse 1 case (60/f) ... Carcinoma Ex Pleomorphic Adenoma Presented as a Gigantic Tumor: Treatment and Diagnostic Challenges.. ...
thefreelibrary.com
Neurosecretory cell | definition of neurosecretory cell by Medical dictionaryNeurosecretory cell | definition of neurosecretory cell by Medical dictionary
... they are increased in chromophobe adenomas.. Claudius cells cuboidal cells, which along with Böttchers cells form the floor of ... chromophobe cell. Chromophobe.. Clara cell. A cuboidal epithelial cell found in the lining of the terminal and the respiratory ... chromophobe cells faintly staining cells in the adenohypophysis; some are nongranular (either nonsecretory, immature ...
medical-dictionary.thefreedictionary.com
Cushings Help and SupportCushing's Help and Support
Chromophobe: Chromophobe adenoma; pituitary adenoma; undifferentiated cell adenoma; an adenoma of the hypophysis composed of ... Chromophobe adenoma: Tumor of the anterior portion of the pituitary gland.. Chronic: Term used to describe long-lasting ... Pituitary Adenoma: Pituitary adenomas cause most cases of Cushings syndrome. They are benign, or non-cancerous, tumors of the ... Adrenal gland tumor: A benign tumor, or adenoma, that usually results in the excess production of adrenal gland hormones. ...
cushings-help.com
17 - Renal Pathology III Flashcards by Andrea Okas | Brainscape17 - Renal Pathology III Flashcards by Andrea Okas | Brainscape
Chromophobe RCC - 5%. - Loss of multiple chromosomes resulting in hypodiploidy. - Prognosis is the best among 3 histotypes. ... Describe a papillary adenoma - Always within the cortex. - AKA "cortical adenoma". - Small. - Usually ...
brainscape.com
Toxic Diffuse Goiter disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsToxic Diffuse Goiter disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
chromophobe adenoma 10.1. SERPINA7 TRH 33. atypical follicular adenoma 10.0. CALCA TG ...
malacards.org
CiNii 論文 - Supradiaphragmatic ectopic adrenocorticotropic hormone-secreting adenoma ...CiNii 論文 - Supradiaphragmatic ectopic adrenocorticotropic hormone-secreting adenoma ...
Large invasive chromophobe adenoma with well-preserved pituitary gland : Report of a case. KEPES J. J. ... Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function ... Supradiaphragmatic ectopic adrenocorticotropic hormone-secreting adenoma * * Jung Shin JUNG Shin * Departments of Neurosurgery ... Supra-diaphragmatic Pituitary Adenoma Removed Through the Trans-tuberculum Sellae Approach : Case Report KINOSHITA Yasuyuki , ...
ci.nii.ac.jp
Radiation Oncology/CNS/Pituitary adenoma - Wikibooks, open books for an open worldRadiation Oncology/CNS/Pituitary adenoma - Wikibooks, open books for an open world
429 patients (acromegaly 72%, Cushings disease 13%, chromophobe adenoma 8%, prolactin-secreting adenoma 4%, Nelsons syndrome ... 16 women, prolactin-secreting adenoma. Narrow beam proton therapy (1000 MeV) 40-120 Gy. Tested 2 month-2 years with IV TRH and ... ITEP, Russia; 1983 PMID 6314085 -- "[Proton therapy of pituitary adenomas][Article in Russian]" (Minakova EI, Med Radiol (Mosk ... Loma Linda; 2006 (1991-2001) PMID 16257131 -- "Fractionated proton beam irradiation of pituitary adenomas." (Ronson BB, Int J ...
en.wikibooks.org
Sarcoma of the sella after radiotherapy for pituitary adenoma | SpringerLinkSarcoma of the sella after radiotherapy for pituitary adenoma | SpringerLink
Chang CH, Pool JL (1967) The radiotherapy of pituitary chromophobe adenomas: an evaluation of indication, technic, and result. ... Pituitary fibrosarcoma secondary to radiation therapy for the treatment of chromophobe adenoma (authors transl). No Shinkei ... Boelaert K, Gittoes NJ (2001) Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 144:569-575CrossRefPubMed ... Fisher BJ, Gaspar LE, Noone B (1993) Radiation therapy of pituitary adenoma: delayed sequelae. Radiology 187:843-846PubMed ...
link.springer.com
Subcutaneous Fat Necrosis - Trip DatabaseSubcutaneous Fat Necrosis - Trip Database
size of papillary adenoma was 5 mm. From now, papillary adenoma is de?ned as a papillary renal tumour =15 mm in ... The main prognostic factors in chromophobe RCC are tumour stage, the presence of necrosis, a sarcomatoid and/or ... Hybrid tumours present overlapping features of oncocyto- mas and chromophobe RCC. They have indolent behaviour ...
tripdatabase.com
Pituitary Tumors: Background, Pathophysiology, EpidemiologyPituitary Tumors: Background, Pathophysiology, Epidemiology
These techniques have identified hormonal production in many chromophobe adenomas, enabling pathologists to identify hormones ... AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med. 2011 Jan 6. 364(1):43-50. [Medline]. ... Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat ... Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev ...
emedicine.medscape.com
HYPOPITUITARISM: STUDIES IN PITUITARY TUMORS AND SIMMONDS DISEASE* | Annals of Internal Medicine | American College of...HYPOPITUITARISM: STUDIES IN PITUITARY TUMORS AND SIMMONDS' DISEASE* | Annals of Internal Medicine | American College of...
The 17 patients studied include cases of pituitary or parapituitary tumors (chromophobe adenomas, craniopharyngiomas) and ...
annals.org
tumor | Tabers Medical Dictionarytumor | Taber's Medical Dictionary
A nonfunctional adenoma of the adrenal or pituitary gland. Endocrine-inactive tumors were formerly known as chromophobe ... adenomas. They are the most commonly detected neoplasms of the pituitary gland. ...
tabers.com
Atrophy of optic nerve fi… - University of Gothenburg, Sweden Atrophy of optic nerve fi… - University of Gothenburg, Sweden
Adenoma, Chromophobe, complications, Adult, Female, Follow-Up Studies, Fundus Oculi, Humans, Middle Aged, Nerve Compression ... The same factors were studied prior to surgery in six patients with compression of the chiasm due to chromophobe adenoma. In ...
gu.se
Amines, N-C12-14 (even... - Registration Dossier - ECHAAmines, N-C12-14 (even... - Registration Dossier - ECHA
The most frequently observed neoplasms were pituitary chromophobe adenomas, adrenal phaeochromocytomas, and tumours of the ...
echa.europa.eu
Remembering Saul R. Korey, M.D.: 50 Years, A Lasting Legacy | The Saul R. Korey Department of Neurology | Albert Einstein...Remembering Saul R. Korey, M.D.: 50 Years, A Lasting Legacy | The Saul R. Korey Department of Neurology | Albert Einstein...
During this time, he wrote his first book, in collaboration with John Nurnberger, called Pituitary Chromophobe Adenomas: ...
einstein.yu.edu
AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and Occupations
Adenoma, ChromophobeAdenomaAdenoma, OxyphilicKidney NeoplasmsCarcinoma, Renal CellPituitary NeoplasmsKeratin-7Adenoma, PleomorphicAdenoma, VillousAdenocarcinoma, Clear CellCalbindin 1Carcinoma, PapillaryMyelin and Lymphocyte-Associated Proteolipid ProteinsAdrenocortical AdenomaAdenoma, Liver CellBirt-Hogg-Dube SyndromeParvalbuminsImmunohistochemistryNephrectomyChromosomes, Human, Pair 10Tumor Markers, BiologicalAdaptor Protein Complex mu SubunitsChromosomes, Human, Pair 1Ossification, HeterotopicChromosomes, Human, Pair 2Growth Hormone-Secreting Pituitary AdenomaColorectal NeoplasmsColonic PolypsACTH-Secreting Pituitary AdenomaAdaptor Protein Complex 1Keratin-20In Situ Hybridization, FluorescenceChromosomes, Human, Pair 6NeprilysinTissue Array AnalysisAdenoma, AcidophilColonoscopyAdenomatous PolypsCalbindinsProlactinomaKidneyChromosomes, Human, Pair 17Adenoma, BasophilChromosome AberrationsAdrenal Cortex NeoplasmsKeratinsOligonucleotide Array Sequence AnalysisGene Expression ProfilingDNA, NeoplasmGene Expression Regulation, NeoplasticReverse Transcriptase Polymerase Chain ReactionImmunoenzyme TechniquesAdenomatous Polyposis ColiNeoplasm ProteinsAcromegalyCushing SyndromeGenes, APCRNA, MessengerPrognosisMembrane ProteinsHyperparathyroidismSalivary Gland NeoplasmsColonic NeoplasmsIntestinal NeoplasmsHyperplasiaNeoplasms, Multiple PrimaryAdrenal Gland NeoplasmsPituitary ACTH HypersecretionParotid NeoplasmsCarcinomaHyperaldosteronismSphenoid BoneDuodenal NeoplasmsAdrenocorticotropic HormonePituitary GlandAdenocarcinomaHyperparathyroidism, PrimaryThyroid NeoplasmsPrecancerous ConditionsSella TurcicaSigmoidoscopy
AcidophilCarcinomasProlactinomaBasophilLesionsNecrosisSuprasellarClinicallyNeuroendocrineHormonalHypothalamusMalignantPathologyRadiotherapyAcromegalyMetabolismSecretionCraniopharyngiomasSurgicalEndocrineAtypicalHyperplasiaAnteriorParathyroidPituitary NeoplasmsCellGalactorrheaDifferentiationDiagnosisCells
Acidophil1
Carcinomas3
Prolactinoma1
  • Possibilities in this case included a previously unrecognized nonfunctioning pituitary adenoma, with hemorrhage related to the anticoagulation, leading to rapid expansion and visual loss, enlargement of a previously unrecognized macro prolactinoma, or an inflammatory mass. (harvard.edu)
Basophil1
Lesions1
  • The present study demonstrated various age-associated lesions of the PD and PN and revealed a high frequency of incidental, non-PPID-associated PI adenomas in aged horses. (uni-muenchen.de)
Necrosis2
Suprasellar3
Clinically9
Neuroendocrine1
Hormonal2
  • Visual disturbances are much less frequent in functional adenomas, where systemic hormonal aberrations such as Cushing's syndrome, galactorrhea, and acromegaly usually predate the compressive signs [ 2 ]. (intechopen.com)
  • Se estudiaron 98 pacientes con adenomas no funcionantes, 34 hombres y 64 mujeres, realizando un estudio hormonal en suero para conocer su perfil endocrino. (bvsalud.org)
Hypothalamus1
Malignant1
  • 5 histopathologic diagnoses submitted by mail on two cases of ependymoma included malignant choroid plexus tumor, chromophobe adenoma, angiosarcoma, medulloblastoma, and 20 "others. (thejns.org)
Pathology1
  • Scinti-graphy using 99mTc-MIBI enabled the correct preoperative localisation of a single parathyroid adenoma in two of these patients and multiglandular pathology in the third. (termsreign.ga)
Radiotherapy3
Acromegaly1
  • en] Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). (ac.be)
Metabolism1
  • Rats with adenomas received fluorodeoxyglucose-positron-emission tomography (FDG-PET) scanning for characterization of tumor metabolism. (ajnr.org)
Secretion1
Craniopharyngiomas1
Surgical1
Endocrine1
Atypical1
Hyperplasia1
Anterior3
Parathyroid1
Pituitary Neoplasms1
Cell5
  • Clear cell and papillary RCC subtypes are both derived from the proximal tubule cells whereas chromophobe RCC is derived from collecting duct intercalated cells in the renal cortex. (renalandurologynews.com)
  • A retrospective study from eight international centers examined outcomes data for 4,163 patients with the three most common forms of RCC: clear cell, papillary, and chromophobe, although these subtypes were not verified by central pathologic review. (renalandurologynews.com)
  • A retrospective review in 2003 by John Cheville, MD, and his colleagues, which looked at outcomes among 2,385 surgically treated sporadic unilateral RCC patients, showed that cancer-specific survival at five years was significantly diminished in patients with clear cell (69%) versus papillary or chromophobe subtypes (87% each). (renalandurologynews.com)
  • Univariate analysis revealed a three-fold increase in mortality among clear cell compared with chromophobe and papillary subtypes. (renalandurologynews.com)
  • We have found that high levels of MN/CA9 expression is seen in all primary RCCs, cystic RCCs, and metastatic RCCs, with the exception of two cases of the chromophobe cell type, which were MN/CA9 negative. (aacrjournals.org)
Galactorrhea1
Differentiation1
Diagnosis3
Cells3